KPTI (Karyopharm Therapeutics) Other Financing : $0.0 Mil (TTM As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Karyopharm Therapeutics Other Financing?

Karyopharm Therapeutics's Other Financing for the three months ended in Sep. 2024 was $0.0 Mil.

Karyopharm Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Sep. 2024 was $0.0 Mil.

Karyopharm Therapeutics Other Financing Historical Data

The historical data trend for Karyopharm Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karyopharm Therapeutics Other Financing Chart

Karyopharm Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Financing

Get a 7-Day Free Trial

78.11

10.31

63.75

3.98

Karyopharm Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Financing	Get a 7-Day Free Trial															-	-	-	-	-

Karyopharm Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

Karyopharm Therapeutics Other Financing Related Terms

Thank you for viewing the detailed overview of Karyopharm Therapeutics's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Karyopharm Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (NAS:KPTI) » Definitions » Other Financing

Comparable Companies

Traded in Other Exchanges

25K:Germany

Address

85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459

Website

https://www.karyopharm.com

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Executives

Richard A. Paulson	director, officer: President and CEO	85 WELLS AVENUE, NEWTON MA 02459
Michael Mason	officer: EVP, CFO, Treasurer	300 3RD STREET, CAMBRIDGE MA 02142
Michael Mano	officer: SVP, General Counsel&Secretary	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Sohanya Roshan Cheng	officer: SVP Sales & Commercial Ops	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON MA 02459
Stuart Poulton	officer: EVP, Chief Development Officer	85 WELLS AVENUE, NEWTON MA 02459
Deepika Pakianathan	director	160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402
Reshma Rangwala	officer: EVP & Chief Medical Officer	RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Garen G Bohlin	director	C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Zhen Su	director	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Stephen Mitchener	officer: SVP, Chief Business Officer	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Ran Frenkel	officer: EVP, WW Development Operations	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, 2ND FLOOR, NEWTON MA 02459
Jatin Shah	officer: EVP, Chief Medical Officer	C/O KARYOPHARM THERAPEUTICS, INC., 85 WELLS AVENUE, NEWTON MA 02459
Sharon Shacham	officer: C.S.O & Pres. of Res & Develop	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Michael Kauffman	director, officer: President, C.E.O., C.M.O.	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Peter Honig	director	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037